Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab and Cetuximab Prior Salvage Surgery in Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma
NCT06448026Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2024
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab, KL-140 in oral cavity squamous cell carcinoma (OCSCC), oropharyngeal squamous cell carcinoma (OPSCC), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2024; status: recruiting.
02
Drugs
cemiplimabKL-140
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT06448026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06448026.